Introduction
Thyroid eye disease is treated with a combination of measures that reduce inflammation, control the autoimmune process, protect the eye surface, and, when needed, correct structural damage caused by swelling and tissue remodeling. The main treatments include restoring stable thyroid function, immunomodulatory medications such as corticosteroids and targeted biologic therapy, local eye care, radiation in selected cases, and surgery for persistent structural problems. These approaches are used because the disorder is driven by immune-mediated inflammation within the tissues behind the eyes, which leads to swelling of the extraocular muscles and orbital fat, forward displacement of the eyeball, and sometimes compression of the optic nerve. Effective treatment aims to slow or stop this biologic process, reduce symptoms such as pain and double vision, prevent vision loss, and restore more normal anatomy and function.
Understanding the Treatment Goals
The treatment goals in thyroid eye disease are shaped by the biology of the condition. The disease begins when immune cells, stimulated in the setting of autoimmune thyroid disease, target antigens in the orbit, especially tissues associated with fibroblasts and connective tissue. These cells release inflammatory mediators that cause tissue swelling, water retention, and production of glycosaminoglycans, which expand the orbital contents. Over time, this can evolve into fibrosis and fixed structural change.
Because of this sequence, treatment has several distinct goals. One goal is to reduce active inflammation before it causes permanent remodeling. Another is to relieve symptoms produced by tissue expansion, including eye irritation, pain, redness, and pressure. A further goal is to protect visual function, especially when swelling compresses the optic nerve or prevents the eyelids from closing properly. In later stages, when inflammation has cooled but structural changes remain, treatment may aim to restore anatomy and improve function through surgical correction. The stage of the disease, whether active or inactive, strongly influences which goal is prioritized.
Common Medical Treatments
Thyroid function control is a core part of treatment, although it does not directly reverse orbital inflammation. Both hyperthyroidism and hypothyroidism can worsen immune instability and may amplify eye disease activity. Restoring stable thyroid hormone levels helps reduce systemic immune stress and creates a more favorable physiologic environment for the orbit. This is why treatment of the thyroid disorder itself is closely integrated with eye disease management.
Corticosteroids are among the most widely used medical treatments for active thyroid eye disease. They are commonly given systemically, often intravenously in moderate to severe disease. Steroids suppress immune activation by reducing cytokine production, limiting leukocyte migration, and decreasing vascular permeability. In practical terms, they blunt the inflammatory edema that causes orbital tissue to swell. This can improve pain, redness, chemosis, and, in some cases, optic nerve compromise. Their main effect is on the inflammatory phase rather than on late fibrosis.
Teprotumumab is a targeted biologic therapy that addresses a specific pathway in thyroid eye disease. It blocks the insulin-like growth factor 1 receptor, which interacts with autoimmune signaling in orbital fibroblasts. By interfering with this receptor-driven process, teprotumumab reduces fibroblast activation, inflammatory swelling, and the accumulation of extracellular matrix material that expands orbital tissues. Because it acts on a disease-specific mechanism rather than broadly suppressing immunity, it can reduce proptosis and improve diplopia in some patients. Its role reflects the growing understanding that orbital fibroblasts are central effector cells in the disease.
Other immunosuppressive agents may be used when steroids are insufficient, not tolerated, or when a steroid-sparing approach is needed. These include medications such as mycophenolate and, in some settings, rituximab or other biologic agents. Their mechanism is to modify immune cell activity and reduce the autoimmune drive that sustains orbital inflammation. Mycophenolate limits lymphocyte proliferation, while rituximab depletes CD20-positive B cells, reducing autoantibody generation and antigen presentation. These treatments are intended to decrease the immune cascade that fuels tissue swelling and subsequent remodeling.
Orbital radiotherapy is sometimes used for active disease, especially when eye movement is restricted and inflammatory enlargement of the extraocular muscles is prominent. Low-dose radiation reduces the inflammatory activity of lymphocytes within the orbit and may limit fibroblast-driven tissue expansion. Its effect is gradual rather than immediate, and it is generally used as an adjunct to medication rather than as a stand-alone therapy. The biological logic is to quiet the local immune process in the orbital tissues before fibrosis becomes fixed.
Local ocular treatments do not alter the autoimmune mechanism, but they reduce the consequences of surface exposure and tear film disruption. Lubricating drops, gels, or ointments help compensate for incomplete eyelid closure and reduced blink efficiency caused by proptosis and lid retraction. By supporting the tear film, these treatments protect the cornea from desiccation and epithelial injury. They address the mechanical effects of the disease rather than the underlying immune process.
Procedures or Interventions
Procedural treatment becomes important when medical therapy cannot prevent functional damage or when the disease has entered a more inactive, fibrotic stage. The main interventions are orbital decompression, strabismus surgery, eyelid surgery, and, in urgent situations, optic nerve decompression.
Orbital decompression surgery is used when proptosis is severe, exposure is significant, or optic nerve compression threatens vision. The orbit is a fixed bony compartment, so inflammation-induced swelling increases pressure and pushes the eye forward. Decompression surgery removes one or more bony orbital walls, and sometimes orbital fat, to expand the available space. This changes the physical structure of the orbit and lowers pressure on the globe and optic nerve. By increasing orbital volume, it reduces forward displacement and can improve exposure and congestion, though it does not eliminate the autoimmune cause.
Strabismus surgery is used when enlarged and fibrotic extraocular muscles produce persistent eye misalignment and double vision. In thyroid eye disease, inflammation can enlarge the muscles and later leave them stiff and shortened. Surgery adjusts the position or length of these muscles to realign the eyes. The procedure addresses a mechanical problem created by tissue remodeling rather than active inflammation, so it is generally reserved for a stable phase when ocular alignment is unlikely to change rapidly.
Eyelid surgery may be performed to correct retraction, improve eyelid closure, or reduce exposure of the cornea. Lid retraction occurs because of fibrosis, abnormal muscle tone, and altered anatomy around the eyelids. Surgical correction modifies these structures to restore better coverage of the eye surface and improve blinking dynamics. This reduces evaporative stress on the cornea and can improve comfort and visual stability.
Urgent decompression or other emergency intervention may be needed if the optic nerve is compressed or if corneal breakdown becomes severe. In these cases, the goal is to rapidly relieve mechanical pressure and preserve tissue perfusion and oxygenation. The underlying principle is simple: when orbital tissues are expanding within a confined space, relieving that pressure can restore function and prevent irreversible damage.
Supportive or Long-Term Management Approaches
Long-term management is important because thyroid eye disease often has an active inflammatory phase followed by a slower, fibrotic phase. During active disease, repeated assessment helps determine whether inflammation is decreasing or whether vision is at risk. Monitoring typically focuses on visual acuity, color vision, eye movement, degree of proptosis, corneal integrity, and signs of optic nerve dysfunction. This follow-up reflects the fact that disease activity can change gradually and structural complications may develop before symptoms become severe.
Supportive care helps reduce the impact of altered eye anatomy on daily function. Surface protection, such as lubrication and nighttime eyelid closure support in selected situations, compensates for exposure from lid retraction or incomplete closure. Elevating the head during sleep may reduce facial and orbital congestion by lowering venous pressure, which can modestly lessen morning swelling. These measures do not modify the autoimmune process, but they reduce the physiologic consequences of orbital crowding and ocular surface drying.
Long-term management also includes attention to the broader endocrine setting. Stable thyroid status is associated with more predictable disease behavior, whereas fluctuating thyroid hormone levels can worsen immune dysregulation. In some patients, smoking cessation is a major part of management because tobacco exposure increases oxidative stress, worsens orbital inflammation, and is associated with more severe eye disease. The mechanism is biologically plausible: smoking amplifies tissue hypoxia and inflammatory signaling, both of which can intensify orbital fibroblast activity.
Factors That Influence Treatment Choices
Treatment selection depends heavily on disease activity and severity. In active thyroid eye disease, the emphasis is on suppressing inflammation and preventing tissue expansion, so corticosteroids, biologic therapy, and sometimes radiotherapy are more relevant. In inactive disease, inflammatory activity has largely settled, and fixed anatomical changes such as proptosis, strabismus, or lid retraction are more often treated surgically.
The specific pattern of involvement also matters. Predominant proptosis suggests orbital volume expansion and may respond well to decompression or targeted biologic therapy. Prominent diplopia points to extraocular muscle involvement, which may be improved by anti-inflammatory treatment during the active phase or by strabismus surgery later. Corneal exposure shifts the focus toward lubrication, eyelid correction, or decompression if the protrusion is severe. Signs of optic neuropathy require faster, more aggressive intervention because the optic nerve is vulnerable to pressure and reduced perfusion within the orbit.
Age, general health, and other medical conditions influence treatment tolerance. High-dose steroids can worsen glucose control, blood pressure, mood, and bone health, so alternative strategies may be preferred in patients at higher risk of steroid toxicity. Immunomodulators may be limited by liver, kidney, or blood count concerns, depending on the agent used. Surgical planning also depends on the patient’s overall medical condition and whether the eye disease is sufficiently stable for a structural correction to remain effective.
Potential Risks or Limitations of Treatment
Each treatment carries limitations because the disease has both inflammatory and structural components. Corticosteroids can reduce swelling quickly, but they do not reverse established fibrosis. Their systemic effects can cause metabolic, psychiatric, infectious, and bone-related complications because they broadly alter immune and hormonal physiology. The benefit is greatest when inflammation is active and tissue damage remains reversible.
Teprotumumab can improve disease manifestations linked to fibroblast activation, but it is not universally effective and may have adverse effects related to its signaling targets, including metabolic disturbances and hearing-related effects in some patients. These risks arise because the IGF-1 receptor is involved in normal tissue function beyond the orbit. Immunosuppressive therapies can increase susceptibility to infection or cause organ-specific toxicity, reflecting their effects on immune regulation throughout the body.
Orbital radiotherapy may help reduce local immune activity, but its benefits are typically modest and delayed. Its use is limited by concerns about radiation exposure to surrounding tissues, and it is generally avoided or used cautiously in certain patients. Surgical procedures can permanently alter orbital anatomy, but they cannot remove the immune tendency that caused the disease. Decompression can change eye position and sometimes worsen double vision if muscle balance is altered, while strabismus and eyelid surgery require stable disease to avoid later relapse or mismatch with ongoing tissue change.
Conclusion
Thyroid eye disease is treated by addressing both the immune-driven inflammation that initiates orbital swelling and the structural changes that follow. Medical therapy is most useful during the active phase, when corticosteroids, targeted biologics, other immunomodulators, and sometimes radiotherapy can reduce inflammatory signaling, tissue edema, and fibroblast activation. Supportive care helps protect the eye surface and manage the mechanical effects of proptosis and eyelid dysfunction. When inflammation has settled or when severe compression persists, surgical procedures such as orbital decompression, strabismus correction, and eyelid surgery restore space, alignment, and closure. The overall treatment strategy is determined by disease activity, severity, and risk of complications, with the central aim of controlling the biologic process while preserving vision and ocular function.